Kargacin B, Kostial K, Arezina R, Singh P K, Jones M M, Cikrt M
Department of Mineral Metabolism, University of Zagreb, Yugoslavia.
J Appl Toxicol. 1991 Aug;11(4):273-7. doi: 10.1002/jat.2550110408.
In the present study the influence of age and time of chelation therapy on cadmium retention in 6-, 11-and 14-day-old rats and in 6-week-old rats has been investigated. Chelating agents N-benzyl-dithiocarboxy-D-glucamine (BDCG), sodium N-(metho-xybenzyl)-D-glucamine dithiocarbamate monohydrate (MeOBDCG) and N-methyl-N-dithiocarboxy-D-glucamine (MDCG) were administered intraperitoneally to three different groups at a dose of 1 mmol kg-1 body weight on two occasions following 115mCd intraperitoneal administration; immediately and after 24 h; after 24 h and 48 h; or after 48 h and 72 h. The 115mCd retention in the whole body and organs was determined 6 days after cadmium administration. Chelation therapy very effectively reduced cadmium retention in the whole body and organs, MeOBDCG being the most effective. The effects of chelating agents were significantly more pronounced in older than younger animals and in the case of early rather than late administration. The highest fraction of cadmium administered was retained in the liver, where also the strongest effect of chelation therapy was observed. Mobilized cadmium was excreted almost exclusively by the faecal route.
在本研究中,已对螯合疗法的年龄和时间对6日龄、11日龄、14日龄大鼠以及6周龄大鼠体内镉潴留的影响进行了研究。螯合剂N-苄基-二硫代羧基-D-葡糖胺(BDCG)、N-(甲氧基苄基)-D-葡糖胺二硫代氨基甲酸钠一水合物(MeOBDCG)和N-甲基-N-二硫代羧基-D-葡糖胺(MDCG)在腹腔注射115mCd后分两次以1 mmol/kg体重的剂量腹腔注射给三个不同的组;分别在注射后立即和24小时后、24小时和48小时后、或48小时和72小时后注射。在给予镉6天后测定全身和各器官中的115mCd潴留情况。螯合疗法非常有效地降低了全身和各器官中的镉潴留,其中MeOBDCG最为有效。螯合剂的作用在年龄较大的动物中比在年龄较小的动物中更显著,在早期给药而非晚期给药的情况下更显著。所给予镉的最大部分潴留于肝脏,在肝脏中也观察到螯合疗法的最强作用。被动员的镉几乎完全通过粪便途径排出。